
a) How will you manage his elevated LDL in view of recent evidence?
b) What is the route of administration and mechanism of action?
c) Name the trial which have studied this drug
d) What was the result
Answers:
a) Evolocumab/ Alirocumab/ PCSK9 Inhibitor
b) Route of administration: Subcutaneous
Mechanism of action: LDL-R in hepatocytes binds to LDL particles and remove them from circulation and returns to cell surface again. PCK9 function as binding protein , binds to LDL – R and promotes their degradation. By blocking PCSK9, these drugs increases availability of LDL-R to remove LDL-C from circulation.
c) Fourier Trial
d) Among patient with elevated LV risk on statin therapy, evolucumab appeared to be effective in reducing adverse CV events and was associated with marked reduction in LDL- C level with similar adverse event as compared to placebo
Reference:
Sabatine MS, et al. "Evolocumab and clinical outcomes in patients with cardiovascular disease". The New England Journal of Medicine. 2017. epub 2017-03-17:1-10.[PubMed]
Comments
Post a Comment
Drop your thoughts here, we would love to hear from you